scholarly journals 10. Recent Advances in the Therapeutic Approaches in Ulcerative Colitis

2015 ◽  
Vol 104 (Suppl) ◽  
pp. 122c-123a
Author(s):  
Mamoru Watanabe
Keyword(s):  
Ulcerative Colitis ◽  
Therapeutic Approaches ◽  
Recent Advances

New Therapeutics for Ulcerative Colitis

2021 ◽  
Vol 72 (1) ◽  
pp. 199-213
Author(s):  
Robert P. Hirten ◽  
Bruce E. Sands
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Disease ◽  
Clinical Remission ◽  
Treatment Options ◽  
Treatment Modalities ◽  
Therapeutic Approaches ◽  
Stages Of Development ◽  
The Future ◽  
New Treatment ◽  
Novel Therapeutic

Ulcerative colitis (UC) is a relapsing and remitting inflammatory disease of the colon with a variable course. Despite advances in treatment, only approximately 40% of patients achieve clinical remission at the end of a year, prompting the exploration of new treatment modalities. This review explores novel therapeutic approaches to UC, including promising drugs in various stages of development, efforts to maximize the efficacy of currently available treatment options, and non-medication-based modalities. Treatment approaches which show promise in impacting the future of UC management are highlighted.

The Emerging Role of Epigenetic Methylation in Kidney Disease

2021 ◽  
Vol 28 ◽  
Author(s):  
Li Wen ◽  
Hong-liu Yang ◽  
Lin Lin ◽  
Liang Ma ◽  
Ping Fu
Keyword(s):  
Dna Methylation ◽  
Kidney Disease ◽  
Histone Methylation ◽  
Kidney Diseases ◽  
Therapeutic Approaches ◽  
Promoter Regions ◽  
Recent Advances ◽  
Epigenetic Methylation

: Kidney disease has complex and multifactorial pathophysiology and pathogenesis. Recent studies have revealed that epigenetic methylation changes, namely DNA methylation, histone methylation and non-histone methylation, are strongly implicated in various forms of kidney diseases. This review provides a perspective on the emerging role of epigenetic methylation in kidney disease, including the effects of DNA methylation in diverse promoter regions, regulation and implication of histone methylation, and recent advances and potential directions related to non-histone methylation. Monitoring or targeting epigenetic methylation has potential to contribute to development of therapeutic approaches for multiple kidney diseases.

Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis

2017 ◽  
Vol 102 (1) ◽  
pp. 70-85 ◽  
Author(s):  
JG Turbeville ◽  
NU Patel ◽  
LA Cardwell ◽  
E Oussedik ◽  
SR Feldman
Keyword(s):  
Small Molecule ◽  
Therapeutic Approaches ◽  
Recent Advances

scholarly journals Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder

Brain ◽  
2019 ◽  
Vol 142 (2) ◽  
pp. 239-248 ◽  
Author(s):  
Abhishek Banerjee ◽  
Meghan T Miller ◽  
Keji Li ◽  
Mriganka Sur ◽  
Walter E Kaufmann
Keyword(s):  
Clinical Trials ◽  
Rett Syndrome ◽  
Therapeutic Interventions ◽  
Diagnosis And Treatment ◽  
Therapeutic Approaches ◽  
Preclinical Models ◽  
Lessons Learnt ◽  
Recent Advances

Fifty years after the first publication on Rett syndrome, Banerjee et al. review the molecular, cellular and circuit neurobiology of the disorder. They summarize recent advances in therapeutic interventions explored in preclinical models, as well as lessons learnt from past clinical trials and how these might inform future therapeutic approaches.

Cystic Fibrosis: New Insights into Therapeutic Approaches

2020 ◽  
Vol 15 (3) ◽  
pp. 174-186
Author(s):  
Antonella Tosco ◽  
Valeria R. Villella ◽  
Valeria Raia ◽  
Guido Kroemer ◽  
Luigi Maiuri
Keyword(s):  
Cystic Fibrosis ◽  
Gene Editing ◽  
New Technologies ◽  
Therapeutic Approaches ◽  
Basic Defect ◽  
Recent Advances ◽  
The Future ◽  
Cftr Protein

Since the identification of Cystic Fibrosis (CF) as a disease in 1938 until 2012, only therapies to treat symptoms rather than etiological therapies have been used to treat the disease. Over the last few years, new technologies have been developed, and gene editing strategies are now moving toward a one-time cure. This review will summarize recent advances in etiological therapies that target the basic defect in the CF Transmembrane Receptor (CFTR), the protein that is mutated in CF. We will discuss how newly identified compounds can directly target mutated CFTR to improve its function. Moreover, we will discuss how proteostasis regulators can modify the environment in which the mutant CFTR protein is synthesized and decayed, thus restoring CFTR function. The future of CF therapies lies in combinatory therapies that may be personalized for each CF patient.

scholarly journals Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Qingdong Guan ◽  
Jiguo Zhang
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Inflammatory Cytokines ◽  
Bowel Disease ◽  
Intestinal Inflammation ◽  
Beneficial Effects ◽  
Recent Advances ◽  
Inflammatory Bowel ◽  
Inflammation Targeting ◽  
Anti Inflammatory

Cytokines play an important role in the immunopathogenesis of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, where they drive and regulate multiple aspects of intestinal inflammation. The imbalance between proinflammatory and anti-inflammatory cytokines that occurs in IBD results in disease progression and tissue damage and limits the resolution of inflammation. Targeting cytokines have been novel strategies in the treatment of IBD. Recent studies show the beneficial effects of anticytokine treatments to IBD patients, and multiple novel cytokines are found to be involved in the pathogenesis of IBD. In this review, we will discuss the recent advances of novel biologics in clinics and clinical trials, and novel proinflammatory and anti-inflammatory cytokines found in IBD with focusing on IL-12 family and IL-1 family members as well as their relevance to the potential therapy of IBD.

Sign in / Sign up

Export Citation Format

Share Document